Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

NOVARTIS : CHF0.50(REGD) Novartis Cosentyx(R) -2-

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/17/2019 | 01:31am EDT
   [6]    Mease PJ, et al. Secukinumab Provides Sustained Improvements in 
the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and 
Safety Results from a Phase 3 Trial. Abstract presented at the American 
College of Rheumatology Annual Meeting, 2018. 
 
   [7]    Bissonnette R et al. Secukinumab demonstrates high sustained 
efficacy and a favorable safety profile through 5 years of treatment in 
moderate to severe psoriasis. Presented as eposter P2223 at 26th EADV 
Congress 2017. 13th September 2017. 
 
   [8]    Baraliakos X et al. Long-term Evaluation of Secukinumab in 
Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 
3 Trial. Presented as a late-breaking abstract at the American College 
of Rheumatology Annual Meeting, 2018. 
 
   [9]    ClinicalTrials.gov. Search of: secukinumab, recruiting, not yet 
recruiting, active, not recruiting, completed, enrolling by invitation 
studies. Listed results on ClinicalTrials.gov [online]. Available from: 
https://clinicaltrials.gov/ct2/results?term=secukinumab&Search=Apply&recrs=b&recrs=a&recrs=f&recrs=d&recrs=e&age_v=&gndr=&type=&rslt= 
[Last accessed: September 2019]. 
 
   [10]  Novartis data on file. September 2019. 
 
   [11]  Landewe R. et al. Clinical Tools to Assess and Monitor 
Spondyloarthritis. Curr Rheumatol Rep. 2015; 17(7): 47. 
 
   [12]  Girolomoni G, et al. Psoriasis: rationale for targeting 
interleukin-17. Br J Dermatol 2012;167:717--724. 
 
   [13]  ClinicalTrials.gov. Search of: secukinumab, recruiting, not yet 
recruiting, active, not recruiting, completed, enrolling by invitation 
studies. Listed results on ClinicalTrials.gov [online]. Available from: 
https://clinicaltrials.gov/ct2/results?term=secukinumab&Search=Apply&recrs=b&recrs=a&recrs=f&recrs=d&recrs=e&age_v=&gndr=&type=&rslt= 
[Last accessed: August 2019]. 
 
   [14]  ClinicalTrials.gov. Comparison of Secukinumab Versus Guselkumab in 
Clearing Psoriatic Plaques Refractory to Ustekinumab (ARROW). 
NCT03553823. Available from: 
https://clinicaltrials.gov/ct2/show/NCT03553823 [Last accessed: August 
2019]. 
 
   [15]  Langley RG, et al. Secukinumab in plaque psoriasis--results of two 
phase 3 trials. N Engl J Med 2014;371:326--338. 
 
   [16]  Blauvelt A, et al. Secukinumab is superior to ustekinumab in 
clearing skin of subjects with moderate-to-severe plaque psoriasis up to 
1 year: Results from the CLEAR study. J Am Acad Dermatol 2017;76:60--69. 
 
   [17]  Bagel J, et al. Secukinumab is Superior to Ustekinumab in Clearing 
Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week 
CLARITY Results). Dermatol Ther 2018;8:571--579. 
 
   [18]  ClinicalTrials.gov. Effect of Secukinumab on Radiographic 
Progression in Ankylosing Spondylitis as compared to GP2017 (Adalimumab 
Biosimilar) (SURPASS). NCT03259074. Available from: 
https://www.clinicaltrials.gov/ct2/show/NCT03259074 [Last accessed: 
August 2019]. 
 
   [19]  MEASURE 2. Novartis data on file. 
 
   [20]  Holdsworth E. et al. Real world physician satisfaction with 
secukinumab in Psoriatic Arthritis and Ankylosing Spondylitis in Europe. 
Presented at EULAR 2019. 
 
   [21]  Michelsen B et al. Remission and drug retention rates of 
secukinumab in 1549 patients with psoriatic arthritis treated in routine 
care -- pooled data from the observational EuroSpA Research 
Collaboration Network. Presented at EULAR 2019. 
 
   [22]  Michelsen B et al. Pooled 6-month treatment outcomes and drug 
retention rates in 1556 patients with axial spondyloarthritis treated 
with secukinumab in routine clinical practice in 12 European Countries 
in the EuroSpA Research Collaboration. Presented at EULAR 2019. 
 
   # # # 
 
   Novartis Global External Communications 
 
   E-mail: media.relations@novartis.com 
 
 
 
 
Antonio Ligi                              Friedrich von Heyl 
 Novartis Global External Communications   Novartis Pharma Communications 
 +41 61 324 1374 (direct)                  +41 61 324 8984 (direct) 
 antonio.ligi@novartis.com                 +41 79 749 0286 (mobile) 
 Eric Althoff                              friedrich.vonheyl@novartis.com 
 Novartis US External Communications 
 +1 646 438 4335 
 eric.althoff@novartis.com 
 
   Novartis Investor Relations 
 
   Central investor relations line: +41 61 324 7944 
 
   E-mail: investor.relations@novartis.com 
 
 
 
 
Central                                  North America 
Samir Shah              +41 61 324 7944  Sloan Simpson  +1 862 778 5052 
Pierre-Michel Bringer   +41 61 324 1065   Cory Twining  +1 862 778 3258 
Thomas Hungerbuehler    +41 61 324 8425 
Isabella Zinck          +41 61 324 7188 
 
 
 
 
 
 

This article is part of a news chaine.
Article 2 / 2
<< Preceding Next >>
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
04:15aGSK to sell two vaccines in $1.1 billion deal to focus on newer treatments
RE
03:58aGlaxoSmithKline to Sell Two Former Novartis Vaccines for up to EUR955 Million
DJ
10/18Sanofi pulls Zantac from U.S. and Canada after carcinogen found
RE
10/17INCYTE : Novartis announces that Jakavi meets primary endpoint in Phase III stud..
AQ
10/17INCYTE : Announces that the REACH2 Pivotal Trial of Ruxolitinib Meets Primary En..
AQ
10/16NOVARTIS : announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase ..
PU
10/16INCYTE : Says Phase 3 REACH2 Trial Meets Endpoint
DJ
10/16Factbox - How are businesses preparing for a 'no-deal Brexit'?
RE
10/15NOVARTIS : Sandoz and Pear Therapeutics announce Pear will solely commercialize ..
AQ
10/14EUROPE : European stocks hit pause as trade doubts linger
RE
More news